Form PTO-1449 (Substituted) (REV. 8-83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.	SERIAL NO.
56613/JPW/GJG/YL	09/166,649
APPLICANTS: Ann Marie Shmidt and David Stern	
FILING DATE: October 5, 1998	GROUP: ~~1615~~ 1646

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EA		Brett, J, et al., (1993) "Survey of the distribution of a newly-characterized receptor for AGEs in tissues" Am. J. Pathol, 143:1699-1712 (Exhibit 2);
EA		Fu, M-X., et al. (1996) "The Advanced Glycation Endproduct, N^{e}-(Carboxymethyl)lysine is a product of both lipid peroxidation and glycoxidation reactions" J. Biol. Chem., 271:9982-9986 (Exhibit 3);
EA		Khoury, J., et al., (1994) "Macrophages adhere to glucose-modified basement membrane via their scavenger receptors" J. Biol. Chem., 269:10197-10200 (Exhibit 4);

EXAMINER Eileen B. O'Hara **DATE CONSIDERED** 6/22/00

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

File Copy

Applicants: Ann Marie Schmidt and David Stern
U.S.Ser.: 09/166,649
Filed: October 5, 1998
Exhibit 1

Form PTO-1449 (Substituted) (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 56613/JPW/GJG/YL	SERIAL NO. 09/166,649
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Ann Marie Schmidt and David Stern	
		FILING DATE October 5, 1998	GROUP ~~1615~~ 1646

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

EA		Lander, H. L., et al. (1997) "Activation of the Receptor for Advanced Glycation Endproducts triggers a MAP Kinase pathway regulated by oxidant stress" J. Biol. Chem., 272:17810-17814 (Exhibit 5);
EA		Li, J. and Schmidt, A. M. (1997) "Characterization and functional analysis of the promoter of RAGE, the Receptor for Advanced Glycation Endproducts" J. Biol. Chem., 272:16498-16506 (Exhibit 6);
EA		Marui, N., et al. (1993) "VCAM-1 gene transcription and expression are regulated through an oxidant-sensitive mechanism in human vascular endothelial cells" J. Clin. Invest., 92:1866-1874 (Exhibit 7);
EA		Miyata, T., et al. (1996) "The Receptor for Advanced Glycation Endproducts (RAGE) mediates the interaction of AGE-b^2-Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implications for the pathogenesis of dialysis-related amyloidosis" J.Clin. Invest., 98:1088-1094 (Exhibit 8);
EA		Park, L., et al. (1998) "Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE)" Nature Medicine, 4:1025-1031 (Exhibit 9);
EA		Portero-Otin, M., et al. (1995) "Chromatographic evidence for pyrraline formation during protein glycation *in vitro* and *in vivo*" Biochim. Biophys. Acta, 1247:74-80 (Exhibit 10);
EA		Reddy, S., et al. (1995) "N^e-(Carboxymethyl)lysine is a dominant Advanced Glycation Endproduct (AGE) antigen in tissue proteins" Biochemistry, 34:10872-10878 (Exhibit 11);
EA		Schleicher, E. D., et al. (1997) "Increased accumulation of the glycoxidation product N^e-(Carboxymethyl)lysine in human tissues in diabetes and aging" J. Clin. Invest., 99:457-468 (Exhibit 12);

EXAMINER	DATE CONSIDERED
Eileen B. O'Hara	6/22/00

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Substituted) (REV. 8-83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.	SERIAL NO.
56613/JPW/GJG/YL	09/166,649
APPLICANTS: Ann Marie Schmidt and David Stern	
FILING DATE: October 5, 1998	GROUP: ~~1615~~ 1646

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

EA		Schmidt, A-M, et al. (1992) "Isolation and characterization of binding proteins for advanced glycation endproducts from lung tissue which are present on the endothelial cell surface" J. Biol. Chem., 267:14987-14997 (Exhibit 13);
EA		Schmidt, A. M., et al. (1997;) "The V-Domain of Receptor for Advanced Glycation Endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetes" Circulation Supplement, 96:#194, p. I-37 (Exhibit 14);
EA		Schmidt, A. M., et al. (1994) "The endothelial cell binding site for advanced glycation endproducts consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide" J. Biol. Chem., 269:9882-9888 (Exhibit 15);
EA		Schmidt, A-M, et al. (1994) "Cellular receptors for advanced glycation end products" Arterioscler. Thromb., 14:1521-1528 (Exhibit 16);
EA		Schmidt, A. M., et al (1995) "The Dark Side of Glucose (News and Views)" Nature Medicine, 1:1002-1004 (Exhibit 17);
EA		Schmidt, A-M, et al. (1993) "Regulation of mononuclear phagocyte migration by cell surface binding proteins for advanced glycosylation endproducts" J. Clin. Invest., 92:2155-2168 (Exhibit 18);
EA		Schmidt, A-M, et al. (1994) "Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins" Proc. Natl. Acad. Sci. (USA), 91:8807-8811 (Exhibit 19);
EA		Schmidt, A. M., et al. (1995) "AGE interaction with their endothelial receptor induce expression of VCAM-1: a potential mechanism for the accelerated vasculopathy of diabetes" J. Clin. Invest., 96:1395-1403 (Exhibit 20);
EA		Schreiber, E., et al. (1989) "Rapid detection of octamer binding proteins with 'mini-extracts' prepared from a small number of cells" Nucleic Acids Research, 17:6419 (Exhibit 21);

EXAMINER Eileen B. Kowa **DATE CONSIDERED** 6/22/00

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Substituted) (REV. 8-83)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 56613/JPW/GJG/YL	SERIAL NO. 09/166,649
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANTS Ann Marie Schmidt and David Stern	
		FILING DATE October 5, 1998	GROUP ~~1615~~ 1646

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
EA		Sell, D. R., and Monnier, V. M. (1989) "Structure elucidation of a senescence cross-link from human extracellular matrix" J. Biol. Chem., 264(36): 21597-21602 (Exhibit 22);
EA		Shamsi, F. A., et al. (1998) "Immunological evidence for methylglyoxal-derived modifications *in vivo*" J. Biol. Chem., 273:6928-6936 (Exhibit 23);
EA		Soulis T., et al. (1997) "Advanced glycation endproducts and their receptors co-localize in rat organs susceptible to diabetic microvascular injury" Diabetologia, 40:619-628 (Exhibit 24);
EA		Vlassara, H., et al. (1995) "Identification of Galectin-2 as a high affinity binding protein for Advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex" Molecular Medicine, 1:634-646 (Exhibit 25);
EA		Wautier, J. L., et al. (1996) "Receptor-mediated endothelial dysfunction in diabetic vasculopathy: sRAGE blocks hyperpermeability" J. Clin. Invest., 97:238-243 (Exhibit 26);
EA		Wu J., et al. (1997) "The soluble receptor for Advanced Glycation Endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice" Plastic Surgery Research Council, Abstract, #77, p. 43 (Exhibit 27);
EA		Yan, S-D., et al. (1994) "Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins" J. Biol. Chem., 269:9889-9897 (Exhibit 28);
EA		Yang, Z., et al (1991) "Two novel rat liver membrane proteins that bind AGEs: relation to macrophage receptor for glucose-modified proteins" J. Exp. Med., 174:515-524 (Exhibit 29).

EXAMINER Eileen B. O'Hara	DATE CONSIDERED 6/22/00

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.